Experienced Executive Advances “Life Sciences” Technologies in SE Ohio< < Back to
Experienced Executive Advances “Life Sciences” Technologies in SE Ohio
Jeff Wiseman has brought his 30 years of experience in “drug discovery research” in pharmaceuticals to Ohio University and SE Ohio.
Wiseman is the Executive in Residence at the Edison Biotechnology Institute at Ohio University. His primary focus is helping to advance “life sciences technologies” from the laboratory to commercial distribution.
He recently talked with WOUB’s Tom Hodson about the growth and value of biotechnology at Ohio University and in this region. Ohio University is one of the nation’s leaders in research licensing revenue, according to The Association of University Technology Managers (AUTM).
Before coming to Ohio University, Wiseman served as the Chief Technology Officer at Locus Pharmaceutical, a biotechnology company. There he participated in raising $32 million in financing and established research collaborations worth $60 million.
Prior to working at Locus, he was the head of discovery divisions at Glaxo-Smith-Kline in biochemistry, informatics, and therapeutics for inflammatory diseases.
In 1994, Wiseman created the discipline of “chemical informatics” and in 1995, he was appointed to Glaxo’s worldwide Research Executive Council.
Wiseman is an undergraduate alumnus of Ohio University in chemistry. He did his doctoral word at Harvard University in chemistry and he did postdoctoral work in biochemistry at Stanford and Brandeis universities.